Long-term Entecavir Therapy Results in Reversal of Fibrosis/Cirrhosis and Continued Histologic Improvement in Patients with HBeAg(+) and (-) Chronic Hepatitis B: Results from Studies ETV-022, -027 and -901

≥10% of patients: upper respiratory tract infection (23%), headache (16%), nasopharyngitis (16%), ALT increase (14%), abdominal pain (13%), influenza (13%), back pain (12%), pyrexia (12%), arthralgia (10%), cough (10%), hypertension (10%), insomnia (10%) and pharyngolaryngeal pain (10%); ‡ One death occurred due to myocardial ischemia and was not attributed to study medication; ± ALT flare = ALT >2 x baseline ALT and >10 x ULN